Oncology Overview: Abemaciclib, a CDK4/6 Inhibitor for Prostate Cancer
June 24th 2022Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512